Nutriband Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended January 31, 2023; comparison is the fiscal year ended January 31, 2022. Although the request identifies “2022 Q4,” this filing reports annual results, not a standalone quarter.
Business context
Nutriband develops transdermal pharmaceutical products, led by AVERSA Fentanyl, an abuse-deterrent fentanyl patch in development. The company also operates contract manufacturing through Pocono Pharmaceuticals and provides research and development services through 4P Therapeutics. No AVERSA product had been approved for sale, and the company had generated no revenue from its pharmaceutical pipeline.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $2.080 million | $1.422 million |
| Gross profit | $750,409 | $504,310 in MD&A; segment note reports $554,310 |
| Gross margin | About 36.1%, calculated from consolidated revenue and cost of revenue | About 35.5%, calculated from MD&A figures |
| Research and development expense | $982,227 | $411,383 |
| Goodwill impairment | $327,326 | $2.181 million |
| SG&A | $3.916 million | $4.023 million |
| Net loss attributable to common shareholders | $4.483 million, or $0.53 per share | $6.373 million, or $0.80 per share, including a $196,589 deemed dividend |
| Cash used in operating activities | $2.987 million | $2.809 million |
| Cash and cash equivalents at year-end | $1.985 million | $4.892 million |
| Working capital | $1.945 million | $4.686 million |
| Total liabilities | $883,387 | $880,375 |
FY2023 revenue comprised $1.786 million from product sales and $294,102 from services. The filing attributes product-sales growth primarily to increased manufacturing demand. Year-end notes payable totaled approximately $120,000; operating lease liabilities totaled approximately $65,600. Investing activities used $79,304, while financing activities provided $160,074, including $296,875 from warrant exercises, partly offset by $119,006 of treasury-stock purchases.
Changes, outlook and key risks
- Revenue increased about 46% year over year, while operating cash use rose about 6%. The net loss narrowed, helped in part by a substantially smaller goodwill impairment; R&D expense more than doubled.
- Management estimates approximately $13 million will be needed to develop AVERSA Fentanyl, including clinical manufacturing and trials; total costs could be higher. The Kindeva feasibility workplan was estimated at about $2.1 million over eight to fifteen months. The company reported $737,654 of expenses incurred by year-end and a $250,000 deposit in prepaid expenses.
- In March 2023, after year-end, Nutriband entered a three-year, $2 million credit-line facility from a shareholder at 7% interest; $50,000 had been advanced by the filing date. Management said projected resources, including this facility, were sufficient for one year and that substantial doubt about continuing as a going concern was alleviated. The company nevertheless continues to incur losses and depend on external capital.
- Principal risks include FDA and clinical-development uncertainty, financing needs, dependence on contract partners, competition, product-liability exposure, and concentrated customers. Two customers accounted for 34% and 14% of FY2023 revenue; one customer represented 94% of year-end receivables.
- Disclosure controls and internal control over financial reporting were reported ineffective, with material weaknesses involving segregation of duties, accounting review, internal audit capacity, and complex transactions. The auditor issued an unmodified opinion on the financial statements but did not audit or opine on internal-control effectiveness.
- The SEC had issued comment letters concerning the company’s MERJ Upstream dual-listing disclosures, and the company expected further comments. The filing also describes a prior SEC reporting settlement and notes market, liquidity, dilution, and Nasdaq-listing risks.
Important facts for investors to verify
- Reconcile reported revenue, gross profit, and segment totals: the filing gives consolidated FY2023 revenue of $2,079,609, but segment disclosures show $2,079,699; reported gross profit also differs between MD&A and the segment note. FY2022 gross profit is likewise inconsistent across sections.
- Confirm the scale, timing, and funding plan for the estimated $13 million AVERSA Fentanyl development program, and the status and remaining cost of the Kindeva workplan and required studies.
- Review actual availability and terms of the post-year-end shareholder credit line, subsequent advances, cash burn, and management’s going-concern assumptions.
- Assess the customer concentration and collection risk associated with one customer comprising 94% of year-end receivables.
- Track remediation of internal-control material weaknesses and the status of SEC comments on the Upstream listing disclosures.